Anergis Closes CHF 5 Million Financing Round Extension to Conduct the ATIBAR Trial

> News > Anergis Closes CHF 5 Million Financing Round Extension to Conduct the ATIBAR Trial

04.04
2016

Anergis Closes CHF 5 Million Financing Round Extension to Conduct Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT.

> Press release Anergis

Anergis Closes CHF 5 Million Financing Round Extension to Conduct the ATIBAR Trial

Biopôle SA

Contact

Newsletter

WAIT, THERE IS MORE!